Orn Focuses on Expanding Sales and Distribution of Wellness Pro Plus Device
SCOTTSDALE, Ariz., March 8, 2022 /PRNewswire/ — InvestorsHub NewsWire — Electromedical Technologies, Inc. (OTC: EMED) (“Electromedical” or the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, is delighted to announce that the Company has hired its first Director of Business Development and Sales, David Orn, to lead a significant expansion of sales and strategic distribution channels for Electromedical’s flagship next-generation Wellness Pro Plus therapy device.
“I couldn’t be more excited to join the electromedical team,” said Mr. Orn. “I see this opportunity as a way to contribute to an enthusiastic, forward-thinking and rapidly evolving company poised to revolutionize the medical device space. I have always been impressed with Electromedical’s culture and leadership. CEO Matthew Wolfson and CIO Petar Gajic demonstrated humility, expertise, drive and an infectious optimistic attitude. I believe that bioelectronics and electroceuticals will have a huge impact on medicine and the opioid crisis. Electromedical Technologies is uniquely positioned to meet the growing demand for self-care and drug-free therapies that help people relieve chronic pain and improve quality of life. I was looking for an opportunity with a company involved in such exciting and innovative work that makes a positive difference in people’s lives. And I’m confident at this point that I’ve found it.”
David is a medical industry veteran, with previous experience working with teams such as Zimmer Biomet and Medtronic, where he developed and oversaw marketing functions to identify key strategies for successful customer acquisition and revenue growth. sales. He has also collaborated with business development, marketing and product development teams in creating competitive concept proposals across various industries.
David has also worked to develop new service offerings based on detailed and documented information related to market and customer needs for regional hospitals and medical groups. His experience includes work to improve the company’s reputation in the marketplace through improvements in go-to-market strategies as well as the creation of new profit centers across multiple industries.
Matthew Wolfson, CEO of Electromedical, said, “David is the perfect addition to our equation right now. We have fruits at hand and great potential in place just waiting to be tapped by someone with their caliber of experience. We are confident that David will help us achieve our fundamental goals in the coming year and for years to come, and we welcome him with open arms as we focus on achieving our fundamental milestones over the next few years. upcoming quarters. catalysts on tap and we look forward to providing additional details in future communications.”
About electromedical technologies
Based in Scottsdale, Arizona, Electromedical Technologies, Inc. is an FDA-registered, bioelectronic medical device manufacturing company initially focused on treating a variety of chronic, acute, intractable, and postoperative pain conditions. Through university collaboration agreements, the Company is working on the development of a comprehensive research program aimed at defining the effects of electromodulation on the human body. By studying the impacts of electric fields in cell signaling and the effects on virus assembly and immune responses, the Company’s goal is to reduce pain and improve overall human well-being. The Company’s current FDA-approved product indications are for the relief of acute chronic post-traumatic and post-operative incurable pain.
For more information, please visit www.electromedtech.com.
Note: The non-human preliminary studies that we plan to initiate in the near future and their applications are in no way related to our current product and are not currently licensed in the United States.
Safe Harbor Statement
This press release contains forward-looking statements based on current expectations or beliefs, as well as on a number of assumptions regarding future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions on which they are based are reasonable, we can give no assurance or guarantee that these expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words such as “may”, “will”, “should”, “could”, “expect”, “anticipate”, “estimate”, “believe”, ” intends” or “project” or the negative of these words or other variations of these words or comparable terminology. The reader is cautioned not to place undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, but not limited to: adverse economic conditions, competition, federal government regulations, unfavorable state and local regulations, international governmental regulations, insufficient capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements contained in this press release are not strictly historical, including statements regarding revenue projections, business strategy, prospects, objectives, future milestones, plans, intentions, objectives , future financial conditions, events subject to shareholder or other approval, or otherwise, with respect to future events, these statements are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
EDM Media, LLC
SOURCE Electromedical Technologies, Inc.
Company Codes: OTC-QB: EMED, OTC-PINK: EMED